With the approval of two CAR-T cell therapies in 2017, the CAR-T cell treatment has been a promising tool for the treatment of advanced hematologic malignancies. However, although a lot of CAR-T cell therapies are under preclinical evaluation, this approach has not been proved to be as successful in solid tumors. One of the limitations in solid tumors lies in the poor penetration of T cells into tumors. To address this need, talented scientists from Creative Biolabs turn to genetically engineered CAR-MA, also termed MOTO-CAR, aiming to improve the ability of CAR cells to attack solid tumors. Learn more: CAR-macrophage